-
Je něco špatně v tomto záznamu ?
The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children
H. Tesfaye, R. Branova, E. Klapkova, R. Prusa, D. Janeckova, P. Riha, P. Sedlacek, P. Keslova, J. Malis,
Jazyk angličtina Země Polsko
Typ dokumentu časopisecké články
PubMed
24811685
DOI
10.12659/aot.889933
Knihovny.cz E-zdroje
- MeSH
- adjuvancia imunologická aplikace a dávkování MeSH
- busulfan aplikace a dávkování škodlivé účinky farmakokinetika MeSH
- dítě MeSH
- dithiokarb aplikace a dávkování MeSH
- intravenózní infuze MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- monitorování léčiv metody MeSH
- myeloablativní agonisté aplikace a dávkování škodlivé účinky farmakokinetika MeSH
- předškolní dítě MeSH
- příprava pacienta k transplantaci škodlivé účinky metody MeSH
- tělesná hmotnost MeSH
- transplantace hematopoetických kmenových buněk metody MeSH
- vysokoúčinná kapalinová chromatografie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- předškolní dítě MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Series of observations indicate PK/PD variability challenging the accuracy of the body-weight based busulfan (Bu) dosing schedule for (HSCT) conditioning therapy. The purpose of this communication is to describe the frequency of dose changes in initially body-weight-based fixed IV Bu dose and to emphasize the importance of TDM. MATERIAL AND METHODS: Sixty-two children (ages 2 months-18 years) were treated with IV busulfan doses based on body weight for myeloablation. TDM utilizing a limited sample strategy (trough concentration immediately before the 5th dose, followed by samples immediately after the end of the 2-h infusion peak, 4 h, and 6 h from initiation of the infusion) was performed in 46 of 62 subjects. Busulfan concentrations were determined by high-performance liquid chromatography (HPLC). AUC was calculated according to the trapezoidal rule. RESULTS: We observed trough levels of 25-1244 µg/L, peak levels of 849-4586 µg/L, and AUC of 2225-12818 µg/L·h following body weight-based high-dose busulfan. The doses were changed in 54% of cases. AUC in 5 of 9 patients with VOD were within target, in 3 patients AUS was higher, and in 1 patient AUC was lower. One of the 2 patients with neurotoxicity had higher AUC. Engraftment was 100%, but relapse occurred in 25% of cases. CONCLUSIONS: Our results demonstrate that even with IV busulfan, intra-individual PK/PD variability is challenging. Although AUC does not necessarily correspond with outcomes (due to the role of other factors the fact that doses were changed in 54% of cases underlines the importance of TDM.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14074216
- 003
- CZ-PrNML
- 005
- 20141007102332.0
- 007
- ta
- 008
- 141006s2014 pl f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.12659/AOT.889933 $2 doi
- 035 __
- $a (PubMed)24811685
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a pl
- 100 1_
- $a Tesfaye, Hundie $u Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 245 14
- $a The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children / $c H. Tesfaye, R. Branova, E. Klapkova, R. Prusa, D. Janeckova, P. Riha, P. Sedlacek, P. Keslova, J. Malis,
- 520 9_
- $a BACKGROUND: Series of observations indicate PK/PD variability challenging the accuracy of the body-weight based busulfan (Bu) dosing schedule for (HSCT) conditioning therapy. The purpose of this communication is to describe the frequency of dose changes in initially body-weight-based fixed IV Bu dose and to emphasize the importance of TDM. MATERIAL AND METHODS: Sixty-two children (ages 2 months-18 years) were treated with IV busulfan doses based on body weight for myeloablation. TDM utilizing a limited sample strategy (trough concentration immediately before the 5th dose, followed by samples immediately after the end of the 2-h infusion peak, 4 h, and 6 h from initiation of the infusion) was performed in 46 of 62 subjects. Busulfan concentrations were determined by high-performance liquid chromatography (HPLC). AUC was calculated according to the trapezoidal rule. RESULTS: We observed trough levels of 25-1244 µg/L, peak levels of 849-4586 µg/L, and AUC of 2225-12818 µg/L·h following body weight-based high-dose busulfan. The doses were changed in 54% of cases. AUC in 5 of 9 patients with VOD were within target, in 3 patients AUS was higher, and in 1 patient AUC was lower. One of the 2 patients with neurotoxicity had higher AUC. Engraftment was 100%, but relapse occurred in 25% of cases. CONCLUSIONS: Our results demonstrate that even with IV busulfan, intra-individual PK/PD variability is challenging. Although AUC does not necessarily correspond with outcomes (due to the role of other factors the fact that doses were changed in 54% of cases underlines the importance of TDM.
- 650 _2
- $a adjuvancia imunologická $x aplikace a dávkování $7 D000276
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a tělesná hmotnost $7 D001835
- 650 _2
- $a busulfan $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D002066
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $7 D002851
- 650 _2
- $a dithiokarb $x aplikace a dávkování $7 D004050
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a monitorování léčiv $x metody $7 D016903
- 650 _2
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a intravenózní infuze $7 D007262
- 650 _2
- $a myeloablativní agonisté $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D019653
- 650 _2
- $a příprava pacienta k transplantaci $x škodlivé účinky $x metody $7 D019172
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Branova, Romana $u Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Klapkova, Eva $u Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Prusa, Richard $u Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Janeckova, Daniela $u Department of Paediatric Hematology and Oncology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Riha, Petr $u Department of Paediatric Haematology and Oncology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic., Prague, Czech Republic.
- 700 1_
- $a Sedlacek, Petr $u Department of Paediatric Haematology and Oncology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic., Prague, Czech Republic.
- 700 1_
- $a Keslova, Petra $u Department of Paediatric Haematology and Oncology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic., Prague, Czech Republic.
- 700 1_
- $a Malis, Josef $u Department of Paediatric Haematology and Oncology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic., Prague, Czech Republic.
- 773 0_
- $w MED00000447 $t Annals of transplantation : quarterly of the Polish Transplantation Society $x 2329-0358 $g Roč. 19, č. - (2014), s. 214-24
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24811685 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20141006 $b ABA008
- 991 __
- $a 20141007102809 $b ABA008
- 999 __
- $a ok $b bmc $g 1042099 $s 873128
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 19 $c - $d 214-24 $i 2329-0358 $m Annals of Transplantation $n Ann Transplant $x MED00000447
- LZP __
- $a Pubmed-20141006